Recent Updates
Recently added Catalysts

carbamazepine

Phase 4

Photosensitive Epilepsy | Small Molecules | Neurology |GSK plc|Trials Updated: Mar 5, 2012

carbamazepine development status

Highest phase Phase 4 run by Novartis (NCT01089855)
Phase scored for GSKPhase 2
Registered trials 40 across 23 sponsors since Sep 2005

carbamazepine target and mechanism

Molecular targetSCN1A, SCN5A, SCN4A, SCN7A, SCN2A, SCN9A
Target classBlocker
ModalitySmall Molecules
ChEMBLCHEMBL108

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment6

FDA Designations

No designations recorded

carbamazepine clinical trials

carbamazepine · 1 trial · 1 indication

Phase 2 1
NCT00894010Photosensitivity Proof of Concept TrialPhotosensitive Epilepsy
COMPLETED6 Analytics
PHASE2COMPLETED
Photosensitivity Proof of Concept Trial
Photosensitive EpilepsyUnlock trial analytics

Study Endpoints

Primary Endpoints

Demonstrate the ability of carbamazepine to suppress or reduce the photosensitivity response in patients with photosensitive epilepsy. Compare the ability of carbamazepine to impact the PPR as compared with levetiracetam, which is known to suppress PPR.
At the completion of each cohort.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT

Interventions

NameTypeDescription
carbamazepine 400mgDRUG -
levetiracetam 1000mgDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Male or female age 18-60 years. * A diagnosis and history of a photoparoxysmal response on EEG with or without a diagnosis of epilepsy for which patients are on 0-1 concomitant antiepileptic drugs. * A reproducible IPS-induced photo-paroxysmal response (PPR) on EEG of at least...

Countries:United States
Unlock Eligibility Criteria